Abstract:The α-Gal (Galα1,3-Galβ1-4GlcNAc-R) epitope, the major xenoantigen, is the first barrier in a porcine-to-man tissue and organ xenotransplantation. The elimination or reduction of the α-Gal epitopes is therefore an important step for a successful xenotransplantation. The present study is to evaluate the α-Gal elimination in the porcine skin with α-galactosidase treatment, and to assess two methods (immunohistochemistry and inhibition ELISA) that may be used in quality control for quantifying the extent of the α-Gal elimination. Enzymatic cleavage in a single-step process is extremely efficient and affordable at eliminating the α-Gal epitope even in a tissue as dense as the porcine dermis. The cost of enzymatic cleavage is found to be less than US$7 for a 10 × 10 cm piece of porcine skin (0.5 mm thick) or about US$140 for 100 g of 3-dimensional soft tissues. After enzymatic cleavage, the α-Gal-positive immunostaining was essentially undetectable in enzyme-treated porcine skin. The inhibition rate constant of the monoclonal anti-Gal antibody M86 binding to α-Gal-bovine serum albumin in ELISA was reduced from 15.0 ± 4.3 (n = 10) to 6.1 ± 2.6 (n = 7) after enzyme treatment, in comparison to 4.4 ± 1.8 (n = 9) background inhibition of decellularized human skin (the ultimate negative control), which demonstrates ∼ 84% elimination of α-Gal epitopes in treated porcine skin. To examine the suitability of two detection methods for the routine quality control application, comparative studies were made with control and enzyme-treated porcine skin, porcine skin from the α-Gal knockout animal, as well as decellularized human skin. The data show that the traditional immunohistochemistry and, to a less extent, the inhibition ELISA with further modifications can be used as quality control tools in the production and selection of biocompatible bioprosthetic devices. The biological evaluation of enzyme-treated porcine skin is ongoing with a small animal model and a nonhuman primate model.

Application of the Isoenzyme Profile in the Development of Cell-Based Devices

Differentiated Fibroblastic Progenies of Human Embryonic Stem Cells for Toxicology Screening

Porous and Single-Skinned Polyethersulfone Membranes Support the Growth of Hepg2 Cells: A Potential Biomaterial for Bioartificial Liver Systems

On-chip real-time impedance monitoring of hiPSC-derived and artificial basement membrane-supported endothelium

Recent Advances in the Determination of Intracellular Contents in Individual Cells Using Microfluidic Devices

Biological characteristics of suckling porcine hepatocytes for bioartificial liver

Quantification of α-Gal Antigen Removal in the Porcine Dermal Tissue by α-Galactosidase

Imitation of drug metabolism in human liver and cytotoxicity assay using a microfluidic device coupled to mass spectrometric detection.

Characterization of Human Pancreatic Islet Cells using a Single-Cell Western Blot Platform

Genetic engineering of porcine endothelial cell lines for evaluation of human-to-pig xenoreactive immune responses

Measurement of Cell-Matrix Adhesion at Single-Cell Resolution for Revealing the Functions of Biomaterials for Adherent Cell Culture.

An Automated Microfluidic Device for Assessment of Mammalian Cell Genetic Stability.

Microfluidic 3D cell culture: potential application for tissue-based bioassays

Comparative Proteomics Study of Freshly Isolated, in Vitro Cultured, and Proliferating Islet Preparation Cells

A Novel In Vitro Method for Detecting Undifferentiated Human Pluripotent Stem Cells as Impurities in Cell Therapy Products Using a Highly Efficient Culture System

Semi-automated digital quantification of cellular infiltrates for in vivo evaluation of transplanted islets of Langerhans encapsulated with bioactive materials

From Chips-in-Lab to Point-of-Care Live Cell Device: Development of a Microfluidic Device for On-Site Cell Culture and High-Throughput Drug Screening

A multiplexed immuno-sensor for on-line and automated monitoring of tissue culture protein biomarkers

Simultaneous Plate-Reader Characterization of Promoter Activity and Cell Growth in Engineered Mammalian Cells

A microfluidic platform with integrated porous membrane cell-substrate impedance spectroscopy (PM-ECIS) for biological barrier assessment

Label-free toxicology screening of primary human mesenchymal cells and iPS-derived neurons